A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.

Bill 118 s 5459, also known as the "Biosimilar Medicare Access Act," aims to make changes to the Social Security Act in order to adjust the eligibility criteria for biosimilar biological products to be included in price negotiations under the Medicare program.

Currently, biosimilar biological products are eligible for price negotiations under Medicare once they have been approved by the Food and Drug Administration (FDA) and are deemed interchangeable with their reference product. However, this bill seeks to alter this criteria to allow biosimilar products to be eligible for price negotiations as soon as they are approved by the FDA, regardless of their interchangeability status.

The main goal of this bill is to increase access to more affordable biosimilar products for Medicare beneficiaries by allowing these products to be included in price negotiations sooner. This could potentially lead to lower costs for both Medicare and its beneficiaries, as biosimilar products are often more cost-effective alternatives to their reference products. Overall, the Biosimilar Medicare Access Act aims to promote competition and lower prices in the Medicare program by expanding the eligibility criteria for biosimilar biological products to be included in price negotiations. This could have a positive impact on both Medicare beneficiaries and the overall healthcare system.